Evolent Health (EVH) Prices Upsized 7.5M Share Common Stock Offering
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Evolent Health, Inc. (NYSE: EVH) announced the pricing of a secondary public offering of 7,500,000 shares of its Class A common stock to be sold by UPMC, certain affiliates of TPG Global, LLC, The Advisory Board Company and Ptolemy Capital, LLC (together, the "Investor Stockholders") and certain management selling stockholders (the "Management Stockholders" and together with the Investor Stockholders, the "Selling Stockholders"). The shares of Class A common stock are being sold to the public at a price of $22.50 per share. The offering was upsized from the previously announced offering size of 7,000,000 shares of Class A common stock. The underwriters have a 30-day option period to purchase up to 1,125,000 additional shares of Class A common stock from the Investor Stockholders. The offering is expected to close on September 14, 2016, subject to customary closing conditions.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC, William Blair & Company, L.L.C., SunTrust Robinson Humphrey, Inc., Allen & Company LLC, Cowen and Company, LLC and Leerink Partners LLC are acting as co-managers.
Evolent Health is not offering any shares of Class A common stock in the offering and will not receive any proceeds from the sale of shares of Class A common stock by the Selling Stockholders, including from any exercise by the underwriters of their option to purchase additional shares from the Investor Stockholders.
A registration statement (including a prospectus) relating to these securities has been filed with the U.S. Securities and Exchange Commission (the "SEC") and has become effective. Before you invest, you should read the prospectus in that registration statement and other documents filed with the SEC for more complete information about Evolent Health and this offering. You may obtain these documents free of charge by visiting EDGAR on the SEC's website at www.sec.gov.
The offering will be made only by means of a prospectus supplement and the accompanying prospectus. Copies of the prospectus supplement and accompanying prospectus related to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 866.803.9204; or Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, facsimile at (212) 902-9316, or email at email@example.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bill Barrett Corporation (BBG) Entered Confidentiality Agreement with Bonanza Creek Energy (BCEI) Pertaining to BCEI's Chapter 11 Proceeding
- Zynerba Pharma (ZYNE) Plans Offering of Common Stock
- Orthofix Int'l (OFIX) Confirms SEC Resolution
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesWilliam Blair, JPMorgan, SunTrust Robinson Humphrey, Cowen & Co, Dividend, Earnings, Wells Fargo, Definitive Agreement, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!